1 week Ago By ABMN Staff
Bank of Montreal Can decreased its stake in shares of BioAtla, Inc. ( NASDAQ:BCAB – Free Report ) by 87.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission.
The fund owned 73,484 shares of the company’s stock after selling 522,252 shares during the quarter. Bank of Montreal Can’s holdings in BioAtla were worth $43,000 at the end of the most recent quarter. A number of other institutional investors have also added to or reduced their stakes in the company.
Magnus Financial Group LLC bought a new position in shares of BioAtla in the 4th quarter valued at about $28,000. Norges Bank acquired a new stake in BioAtla in the 4th quarter valued at about $230,000. Finally, Highbridge Capital Management LLC bought a new position in BioAtla during the fourth quarter worth about $1,484,000.
77.23% of the stock is currently owned by institutional investors and hedge funds. Wall Street Analysts Forecast Growth Separately, HC Wainwright restated a “neutral” rating on shares of BioAtla in a research note on Monday, March 31st.
BioAtla Price Performance BCAB stock opened at $0.44 on Friday. BioAtla, Inc.
has a one year low of $0.24 and a one year high of $3.53.
The stock has a market cap of $25.73 million, a price-to-earnings ratio of -0.26 and a beta of 1.
08. The company has a fifty day moving average price of $0.34 and a two-hundred day moving average price of $0.
90. BioAtla ( NASDAQ:BCAB – Get Free Report ) last posted its earnings results on Thursday, March 27th. The company reported ($0.
32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.08.
Research analysts anticipate that BioAtla, Inc. will post -1.46 EPS for the current fiscal year.
About BioAtla ( Free Report ) BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. Recommended Stories Want to see what other hedge funds are holding BCAB? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for BioAtla, Inc. ( NASDAQ:BCAB – Free Report ). Receive News & Ratings for BioAtla Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAtla and related companies with MarketBeat.
com's FREE daily email newsletter ..
